Objective: To evaluate late PAPP-A levels as predictive of preterm birth in symptomatic women.
Introduction
Preterm delivery accounts for 50 to 70% of neonatal morbidity and mortality. [1] [2] [3] Despite advances in obstetric care, preterm births continue to constitute about 8 to 12% of all births. 4, 5 Hospitalization for preterm contractions with suspected imminent preterm delivery poses a major burden on health services, and costs and accounts for more than one-third of obstetric admissions before delivery. 6, 7 Although used in prenatal genetic screening programs since the 1980s 8 and also for risk assessment of preterm labor, 9 the predictive power of pregnancy-associated plasma protein A (PAPP-A) in the second trimester for preterm delivery is still considered speculative. 10 In assessing the predictive value of first-trimester PAPP-A for preterm delivery and fetal growth restriction in a selected study group of pregnancies achieved via assisted technologies, only weak associations have been found. 11 Nonetheless, women with PAPP-A levels in the lowest percentiles at 8 to 14 weeks gestation have been shown to be at an increased risk of fetal growth restriction, extremely or moderately premature delivery, pre-eclampsia and stillbirth. 12, 13 In the largest series to date, PAPP-A data from 34 271 pregnancies obtained between 10 and 14 weeks gestation showed a very strong association between low PAPP-A levels in the first trimester and several adverse outcomes of pregnancy. 14, 15 PAPP-A had been identified by mass spectrometry microsequencing as the Insulin Growth Factor (IGF)-dependent Binding Protein (IGFBP)-4-specific protease 16 from human fibroblast-conditioned media. 17 Recently, PAPP-A was demonstrated to be a metzincin superfamily metalloproteinase involved in normal and pathological IGF physiology. 18 Differential regulation of decidual PAPP-A by insulin-like peptides suggests that trophoblast-derived IGF-II is a paracrine regulator of maternal decidual products that in turn regulates IGF-II at the trophoblast -decidual interface possibly as a cofactor during implantation. 19 As with other metalloproteinases, PAPP-A expression has been shown to be regulated by inflammatory cytokines such as TNF-a, IL-1b and IFNg. 20 These data provide a mechanism for the regulation of PAPP-A in response to injury and further implicate PAPP-A as an acute reactant in inflammatory processes, one of which may be preterm labor. The purpose of the present study is to evaluate late, 'at admission', PAPP-A levels as a predictor of preterm birth in women with complaints of preterm painful contractions, that is threatened preterm birth.
Methods
A prospective cohort study was undertaken of consecutive admissions of women with a singleton gestation between 23 and 34 weeks and a diagnosis of spontaneous preterm labor. All women receive antenatal care, which is under the National Health Plan, independent of ethnic origin. Both maternal referral and neonatal care in our tertiary center have full financial coverage.
All women with a complaint of regular, painful contractions (at least three in 10 min) on monitor and cervical dilatation of X3 cm and/or effacement of >80% were initially included. Exclusion criteria into this study were multifetal pregnancy, cerclage, ruptured membranes, vaginal bleeding, evidence of clinical chorioamionitis, uterine malformation, known fetal abnormality, intrauterine growth restriction and/or coexistence of maternal complications (trauma, hypertension, diabetes).
Preterm labor management upon admission was according to our group's standard practice and included betamethasone with 24 to 48 h of tocolysis (choice of either indomethacin, calcium blocker, or MgSO 4 ). The admission management was entirely unrelated to the PAPP-A results. Our departmental policy does not include the routine use of vaginal fibronectin test due to its expense. Urogenital cultures were obtained at admission (vaginal swab and urine cultures). Cultures were defined positive for group B Streptococcus (GBS) in either vaginal or urine culture or any microbial growth >100 000 ml À1 in the urine culture. The results of the cultures are reported within 24 to 48 h of admission. Maternal blood samples are obtained at admission as soon as routine intravenous access is established. Umbilical blood samples are obtained at delivery. Plasma is stored at À701C for less than 60 days until thawing and analysis.
PAPP-A and IGF-I and IGF-III analysis were performed in triplicate by a laboratory blinded to identity by standard methods (Wallac, Tuku, Finland, CR 61 to 105) and with appropriate dilutions (Delfia Diluent II). Results are expressed in mIU l
À1
. PAPP-A polyclonal antibodies were used for capture; a combination of monoclonal antibodies was used for detection. The assay was calibrated against the WHO international reference standard 78/610 for pregnancy-associated proteins. Free IGF-I and IGF-III were measured by commercially available immunoradiometric assays (Diagnostic Systems Laboratories, Webster, TX, USA) using Imulitet 2000; results were expressed in nanogram per milliliter.
Statistical analysis
Two groups were compared: Group 1 consisted of women who delivered p7 days from onset of symptoms; and Group 2 included women who delivered >7 days.
Differences between groups were determined using w 2 or Fisher's exact test for categorical variables, as appropriate, Student's t-test for continuous variables normally distributed, and the Mann-Whitney U-test for variables without normal distribution. Medians and the inter-quartile range (IQR), which is the 25%ile to the 75%ile, were calculated where appropriate. Receiver operating characteristic (ROC) curves were constructed for various PAPP-A cutoff values to predict preterm delivery at p7 days.
Analyses were performed with SPSS 12.0 software, (SPSS, Chicago, IL, USA). Data are presented as mean±s.d. unless stated otherwise. Tests were considered statistically significant at a P-value (two-sided) <0.05. The study was performed according to the institutional ethical committee (Helsinki Committee) guidelines and received approval from the IRB.
Results
During the study period, 51 women were considered eligible for study inclusion: 26 women (51%) delivered p7 days (Group 1) and 25 women (49%) delivered afterwards (Group 2). There were no statistically significant differences between the groups for maternal age, educational status, smoking, parity, antenatal care, previous preterm birth, gestational age at enrollment or positive vaginal/urinary cultures ( Table 1) . The positive urogenital cultures in Group 1 are comprised of four patients with GBS positive vaginal cultures and two with asymptomatic bacteriuria (Escherichia coli) while in Group 2 there were two positive GBS vaginal cultures.
Mean PAPP-A value for Group 1 was 38 000 (s.e.±4604) with a median of 34 850 (IQR 17 712 to 45 450) which were significantly lower than the mean value of 55 333 (s.e.±5059) and median value of 49 250 (IQR 35 225 to 77 750) for Group 2 (P ¼ 0.04 for mean comparison; P ¼ 0.014 for the median). Furthermore, in Group 1 the mean gestational age at delivery was 29.6 weeks (s.e.±0.5), median 30.2 (IQR 27.8 to 31.7) while in Group 2 the mean gestational age was 37 weeks (s.e.±0.6), median 37.6 (IQR 35.4 to 39.7) at delivery (P<0.001 for mean comparison; P ¼ X for median comparison) (see Table 2 ) (Figure 1) .
Interestingly, a threshold PAPP-A level of p30 000 mU l À1 had a specificity of 88% and a sensitivity of 50% with a positive predictive value of 81% (Table 3) for identification of women who were likely to deliver within a week of symptoms, with a likelihood ratio of 4. The ROC analysis for Group 1 had an area under the curve of 0.703 (s.e.±0.074) (Figure 2) . Levels of IGF-I and IGF-III did not differ significantly between groups: 176.08±12.95 vs 197.80±17.57 and 5.21±0.28 vs 5.88±0.53, respectively. PAPP-A level in the umbilical vein blood samples were close to null in all samples, independent of the group.
Discussion
After decades of extensive research, preterm birth remains a challenging problem for modern medicine. The identification of women at risk for preterm delivery is thought to facilitate initiation of risk-specific interventions to improve maternal and neonatal outcome, for example maternal transfer to a tertiary care center, corticosteroid therapy and in the future, effective tocolysis. No less important is the awareness of factors that identify women who will have a preterm birth in illuminating the putative pathways that result in preterm birth.
Although a number of historical and epidemiological risk factors for preterm delivery have been identified and included in scoring systems, these have been insufficient to positively identify women who will ultimately deliver preterm. 21 Markers that are found in biologic fluids are of great interest to both researchers and clinicians because of the potential for finding threshold values that may be predictive of outcomes and both identify women at highest risk as well as exclude women with low risk. 22 Ideally, an important goal would be to identify a readily measurable marker with a high positive predictive value in a low-risk population.
A variety of markers are being investigated; however, to date only negative predictors such as fetal fibronectin and salivary estriol have achieved FDA approval. 23, 24 No marker has been PAPP-A as marker for preterm birth S Grisaru-Granovsky et al implicated in large low-risk populations or has its use been validated against reduction of preterm birth. 23, 24 Moreover, in practice, the use of fibronectin in the cervicovaginal secretion is limited and may be delayed by the presence of blood, leaking amniotic fluid, intercourse in the previous 24 h, previous digital examination and/or the use of transvaginal ultrasound scan gel. 25 The most recent evidence points to amniotic fluid inflammatory interleukins as having high predictive value for preterm delivery. 26 Similar to C-reactive protein, the presence of abnormal interleukin levels imply that an inflammatory condition is part of the pathology of preterm labor. However, assessment of very specific inflammatory biochemical markers of preterm birth, such as interleukin 6 require both an invasive procedure (amniocentesis) and costly, sophisticated laboratory facilities. 27 While others have suggested the predictive value of PAPP-A in preterm labor, [6] [7] [8] [9] [10] [11] [12] [13] this work was primarily based on PAPP-A values obtained at an early gestational age, most often in the first trimester. Interestingly, the structural sequence of PAPP-A is characterized by five short consensus repeats seen in components of the complement system. [16] [17] [18] [19] In predicting an inflammatory etiology for preterm birth, we reasoned that complement system activation in the context of a generalized inflammatory reaction would induce consumption of the 'complement-like' PAPP-A in the context of imminent early delivery. Our study shows that PAPP-A levels p30 000mU l À1 at admission for evaluation of preterm birth implicate a fourfold greater risk of delivery within 7 days. These levels are apparently different from those that can be measured in the first trimester because IGF levels are not elevated. In parallel, the low umbilical blood PAPP-A values make a possible fetal signal less likely. The high positive predictive value of 81% in conjunction with a negative predictive value of 62% for delivery within 7 days is comparable and perhaps superior to that reported 28 for fetal fibronectin in patients with symptoms of preterm birth (23 and 93% respectively). Thus, we will withhold intervention in patients with a negative result while supporting intervention for those in the risk group.
PAPP-A levels are obtained from maternal blood and are independent of previous interventions and conditions such as fibronectin levels. 28 This cohort, while relatively small, has a minimal number of maternal confounding variables because socio-economic factors were rather uniform and an unbiased standard protocol was used. However, there may be other potential confounders that we did not consider or that were not available for analysis. We did identify a difference in the type of tocolytics 20 000  27  96  87  55  25 000  31  92  80  55  30 000  50  87  81  62  35 000  50  75  68  58  40 000  50  75  68  58  45 000  77  62  69  71  50 000  80  45  61 PAPP-A as marker for preterm birth S Grisaru-Granovsky et al utilized in the two groups, which may provide some evidence of potential bias. However, there is no consistent, clear evidence that tocolytic drugs improve the outcomes of preterm labor or delay preterm birth more than 48 h. Thus, the variety of tocolytic drugs used to achieve the 48-h delay for the steroid-induced fetal lung maturation likely had minimal influence on the conclusions of this study. 29 Despite the good-quality antenatal care and the low background socioeconomic risk, the percentage of patients with a history of previous preterm birth is rather high in both the study groups, 23 and 36% respectively. We assume that this reflects the fact that the study was performed in a tertiary center admission service and not in a primary care facility. Although this risk factor is similar for both groups, it may circumscribe our conclusion based on a positive predictive value and may limit our conclusion to a rather select population. However, it does not bias the cutoff level resulted from comparison of the study groups and the concept of lower third-trimester PAPP-A values for women at risk as a distinct phenomenon from first-trimester test. The limited size of the study also prevents us from calculating Multiples of the Median of PAPP-A and/or building a better predictive model to establish the predictive value of late PAPP-A values relative to other biochemical or ultrasonographic values as described in the literature.
Our study, despite the above limitations, suggests a simple maternal blood test that can be readily performed in a routine laboratory setting. It is not limited by maternal conditions and our recommended cutoff value has a relative high-positive predictive value in a population with symptoms of preterm labor. In addition, we showed that late low values of maternal PAPP-A are independent of first-trimester values, and are probably related to the inflammatory cascade released in symptomatic cases that will proceed to preterm birth.
Thus, the positive predictive value of low levels of PAPP-A in women with symptoms of preterm birth may be used to support an active management and therapeutic approach. In the future, the value of various markers of preterm birth, alone or in combination, will have to be validated in larger low-risk populations.
